Platelet factor 4 (PF4)/heparin and protamine/heparin (PRT/heparin) complexes elicit antigen-specific antibodies in 25 to 50% of heparin-exposed patients in certain clinical settings. In recent studies, we showed that antibody response to protein/heparin complexes may, in part, be derived from their complement-activating properties. These studies, performed with flow-based assays, showed that PF4/heparin ultra-large complexes (ULCs) added to blood of healthy donors, or generated in situ in patients receiving heparin, activate complement in a heparin-dependent manner leading to selective binding of antigen to B cells via complement receptor 2/CD21. These studies also showed that complement activation by PF4/heparin complexes occurs in plasma and not on the cell surface.

Flow-based techniques, however, are cumbersome, costly and require technical expertise. To circumvent these limitations, we have developed a robust and simple two-stage functional capture immunoassay for detecting complement activation by PF4/heparin complexes. In this communication, we show that an antigen-C3 capture immunoassay can be used for studying mechanisms of immune activation, examining complement activating effects of variant heparins and investigating the therapeutic potential of complement inhibitors.

In this assay, plasma is first incubated with PF4/heparin complexes (25 µg/mL and 0.25 U/mL, respectively; formed at a PF4:heparin molar ratio [PHR] of 6.6), or equivalent amounts of PF4 alone, heparin alone or buffer. After a 1-hour incubation complement-fixed antigen is captured by KKO, a PF4/heparin-specific monoclonal antibody and complement fragments containing C3 are detected using a biotinylated anti-C3c antibody (please refer to the Supplementary Material section for detailed methods, available in the online version). As shown in Fig. 1A, this assay detects the activation of complement as indicated by bound C3c to captured PF4/heparin complexes, but not when plasma is incubated with equivalent amounts of PF4 alone, heparin alone or buffer. The degree of complement activation by PF4/heparin complexes seen in this assay relative to PF4 or heparin alone is comparable to findings using flow cytometry endpoints (Fig. 1B). In data not shown, we demonstrate that a polyclonal rabbit anti-PF4 antibody recognizing both PF4 and PF4/heparin complexes could substitute for KKO in the immunoassay, albeit with a higher background.

To demonstrate requirements for an intact complement pathway, we inhibited complement by using ethylenediaminetetraacetic acid (EDTA), ice or the cyclic peptide complement inhibitor Cp40 and examined PF4/heparin-induced complement activation. As shown in Figs. 1C and D, C3 generation by PF4/heparin complexes is abrogated if complement is inhibited by EDTA, ice (0°C temperature) or the C3/C3b inhibitor, Cp40.

The observation that Cp40 (Fig. 1D) significantly inhibits PF4/heparin-triggered complement activation suggests a potential therapeutic role for these inhibitors in the prevention of anti-PF4/heparin antibodies that trigger heparin-induced thrombocytopenia (HIT). This strategy may be particularly effective for patients undergoing cardiopulmonary bypass, many of who develop anti-PF4/heparin antibodies after a one time exposure.
Fig. 1 (A) Antigen-C3 capture immunoassay detects complement activation by platelet factor 4 (PF4)/heparin complexes in plasma. Plasma from a healthy donor was incubated with buffer or antigen (PF4, 25 μg/mL ± heparin 0.25 U/mL) or heparin alone (0.25 U/mL) and binding of C3c was determined by enzyme-linked immunosorbent assay (ELISA) as described in Supplementary Methods. The bar graph shows the anti-C3c absorbance in different incubation conditions. (B) Flow-based method for complement activation by PF4/heparin complexes. Whole blood from a healthy donor was incubated with buffer or antigen (PF4, 25 μg/mL ± heparin, 0.25 U/mL) or heparin alone (0.25 U/mL) and the binding of C3c to the B cells was determined by flow cytometry. The bar graph shows the % of C3c-positive B cells in different incubation conditions. (C) Antigen-C3c immunoassay is sensitive to complement inhibition. Plasma from a healthy donor was incubated with buffer or antigen (PF4, 25 μg/mL ± heparin 0.25 U/mL) in presence or absence of 10 mM ethylenediaminetetraacetic acid (EDTA) for 60 minutes at 37°C or 0°C and the binding of C3c to the complexes was determined by ELISA with a KKO-coated plate. The bar graph shows the anti-C3c absorbance in different conditions. (D) Peptide C3 inhibitor Cp40 inhibits complement activation by PF4/heparin complexes. Plasma from a healthy donor was incubated with buffer or antigen (PF4, 25 μg/mL ± heparin, 0.25 U/mL) in the presence or absence of 5 μM Cp40 or control (Ctrl) peptide and binding of C3c was determined by ELISA with a KKO-coated plate. The bar graph shows the anti-C3c absorbance in different incubation conditions. (E) Complement activation by PF4/unfractionated heparin (UFH) and PF4/glycosaminoglycans (GAGs). Plasma from a healthy donor was incubated with fixed doses of PF4 (25 μg/mL) and varying doses of UFH (0.0005–5.0 U/mL) or GAGs (0.01–500 μg/mL) and the binding of C3c to the PF4/heparin or PF4/GAGs complexes was determined by ELISA as described in Supplementary Methods. The graph shows the anti C3c absorbance at different concentrations of UFH or different GAGs. (F) Detection of complement activation by protamine (PRT)/heparin complexes. Plasma from a healthy donor was incubated with buffer or PRT (100 μg/mL ± heparin (10 U/mL) or heparin alone (10 U/mL) and binding of C3c was determined by ELISA on an anti-PRT/heparin antibody (ADA)-coated plate. The bar graph shows the anti C3c absorbance in different incubation conditions. (G) Comparison of complement activation by porcine and bovine (E1 and E2) UFH. Plasma from a healthy donor was incubated with fixed doses of PF4 (25 μg/mL) and varying doses of porcine or bovine UFH (0.0005–5 U/mL) and the binding of C3c to the PF4/heparin complexes was determined by ELISA with a KKO-coated plate. The graph shows the anti C3c binding at different concentrations of porcine/bovine UFH.
Other applications of the antigen–C3 capture immunoassay include investigations of pathogenic mechanisms in HIT. Recent studies have shown that autoimmune HIT arises from host reactivity to PF4/glycosaminoglycans (GAGs) complexes. To determine if PF4/GAG complexes are comparable to PF4/heparin complexes in eliciting complement activation, we used a fixed concentration of PF4 and variable doses of GAGs in the antigen–C3 immunoassay. As previously shown, we noted a bell-shaped response for complement activation using PF4/unfractionated heparin (UFH) complexes, with maximal C3c detection occurring at PHRs of 1.6. Not surprisingly, complexes of PF4 and dextran sulphate, a highly sulphated bacterial-derived glucan, showed robust complement activation (PHR, 0.64). However, we noted minimal complement activation by PF4/heparin, are being clinically developed due to concerns over immunogenicity and likely account for their in vivo vulnerability of the porcine heparin supply chain as the sole source of pharmaceutical heparin. Other animal sources of heparin, such as bovine and ovine heparin, are being clinically developed due to concerns over vulnerability of the porcine heparin supply chain as the sole source of pharmaceutical heparin. As the antigen–C3 immunoassay can readily assess the complement-activating properties of variant heparins, we compared two bovine heparins (E1 and E2) with commercial porcine heparin. Using a fixed dose of PF4 (25 μg/mL) and equipotent concentrations of porcine or bovine UFsHs (0.0005–5 U/mL), we showed differences in the complement activating profiles of the two bovine heparins relative to porcine heparin (Fig. 1G). Whereas low concentrations of porcine and bovine heparins were similar with respect to complement activation (concentrations 0.0005–0.005 U/mL), porcine heparin at concentrations of 0.1 to 1 U/mL, appeared to have stronger complement-activating effects. While additional in vivo studies are needed to correlate complement activation with immunogenicity, this assay is nonetheless useful for comparative investigations of biosimilar heparins.

In summary, we show the utility of a simple and rapid functional immunoassay for investigating complement-activating effects of PF4/heparin complexes. In addition to understanding fundamental mechanisms related to the immune pathogenesis of HIT, this assay will be helpful for facilitating studies of complement therapeutics and biologic characterization of generic and/or novel heparins under development.

Authors’ Contributions

Note
This article reflects the views of the authors and should not be construed to represent Food and Drug Administration’s views or policies. This study was performed in part at the 58th Annual meeting of American Society of Hematology at San Diego, CA, 2016.

Funding
This study was supported by the National Institutes of Health P01 HL110860 (G.M.A.) and AI030040 (J.D.L.)

Conflict of Interest
G.M.A. has an awarded patent for KKO (U.S. Application NO 60/143,536). J.D. Lambris is the founder of Amyndas Pharmaceuticals, which is developing complement inhibitors (including third-generation compstatin analogs such as Cp40/AMY-101), inventor of patents or patent applications that describe the use of complement inhibitors for therapeutic purposes, some of which are developed by Amyndas Pharmaceuticals. J.D. Lambris is also the inventor of the compstatin technology licensed to Apellis Pharmaceuticals (i.e. 4(1MeW)7W/POT-4/PLT-1 and PEGylated derivatives such as APL-2). The other authors declare no conflict of interest.

References
5 Warkentin TE, Basciano PA, Knopman J, Bernstein RA. Spontaneous heparin-induced thrombocytopenia syndrome: 2 new cases and a proposal for defining this disorder. Blood 2014;123(23):3651–3654